Related Experiment Video
Updated: Jun 6, 2026
A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
Published on: March 29, 2024
Lipotoxicity and the development of heart failure: moving from mouse to man
William C Stanley1, Fabio A Recchia
1Division of Cardiology, Department of Medicine, University of Maryland, Baltimore, MD 21201, USA. wstanley@medicine.umaryland.edu
Abstract:
Intracardiac lipid accumulation can cause heart failure. A study in Journal of Clinical Investigation (Son et al., 2010) found that cardiac-specific PPARγ overexpression caused heart failure with intracardiac triglyceride accumulation. Overexpressing PPARγ on a PPARα-/- background improved cardiac function, suggesting that specific lipid metabolites and lipid packaging determine cardiac lipotoxicity.
Insights
Cardiac lipid buildup causes heart failure. Modulating specific lipid pathways, like PPARγ, can improve heart function by altering lipid metabolism and storage.
Area of Science:
- Cardiology
- Molecular Biology
- Metabolic Diseases
Background:
- Intracardiac lipid accumulation is a known contributor to heart failure.
- Peroxisome proliferator-activated receptor gamma (PPARγ) plays a role in lipid metabolism.
Discussion:
- Cardiac-specific overexpression of PPARγ leads to heart failure and triglyceride buildup.
- PPARγ's role in lipotoxicity is context-dependent, influenced by other factors like PPARα.
- Altering lipid metabolism pathways can impact cardiac function.
Key Insights:
- Overexpressing PPARγ in the heart causes lipotoxicity and heart failure.
- PPARγ's detrimental effects can be mitigated by manipulating the genetic background (e.g., PPARα-/-).
- Specific lipid metabolites and their intracellular packaging are critical determinants of cardiac lipotoxicity.
Outlook:
- Further research into lipid metabolism and packaging could reveal new therapeutic targets for heart failure.
- Understanding the interplay between PPAR isoforms may offer novel strategies for managing cardiac lipid disorders.
- Targeting specific lipid pathways presents a potential avenue for treating lipotoxic cardiomyopathy.
